1. Home
  2. CTKB vs AURA Comparison

CTKB vs AURA Comparison

Compare CTKB & AURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CTKB
  • AURA
  • Stock Information
  • Founded
  • CTKB 1990
  • AURA 2007
  • Country
  • CTKB United States
  • AURA United States
  • Employees
  • CTKB N/A
  • AURA N/A
  • Industry
  • CTKB Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • AURA Biotechnology: Pharmaceutical Preparations
  • Sector
  • CTKB Health Care
  • AURA Health Care
  • Exchange
  • CTKB Nasdaq
  • AURA Nasdaq
  • Market Cap
  • CTKB 430.6M
  • AURA 396.8M
  • IPO Year
  • CTKB 2021
  • AURA 2021
  • Fundamental
  • Price
  • CTKB $3.69
  • AURA $7.23
  • Analyst Decision
  • CTKB Hold
  • AURA Strong Buy
  • Analyst Count
  • CTKB 4
  • AURA 6
  • Target Price
  • CTKB $6.00
  • AURA $22.33
  • AVG Volume (30 Days)
  • CTKB 960.6K
  • AURA 205.3K
  • Earning Date
  • CTKB 08-05-2025
  • AURA 08-07-2025
  • Dividend Yield
  • CTKB N/A
  • AURA N/A
  • EPS Growth
  • CTKB N/A
  • AURA N/A
  • EPS
  • CTKB N/A
  • AURA N/A
  • Revenue
  • CTKB $197,050,000.00
  • AURA N/A
  • Revenue This Year
  • CTKB $0.91
  • AURA N/A
  • Revenue Next Year
  • CTKB $7.75
  • AURA N/A
  • P/E Ratio
  • CTKB N/A
  • AURA N/A
  • Revenue Growth
  • CTKB N/A
  • AURA N/A
  • 52 Week Low
  • CTKB $2.37
  • AURA $4.35
  • 52 Week High
  • CTKB $7.63
  • AURA $12.38
  • Technical
  • Relative Strength Index (RSI)
  • CTKB 60.88
  • AURA 61.99
  • Support Level
  • CTKB $3.20
  • AURA $6.72
  • Resistance Level
  • CTKB $3.44
  • AURA $7.15
  • Average True Range (ATR)
  • CTKB 0.18
  • AURA 0.36
  • MACD
  • CTKB 0.01
  • AURA 0.04
  • Stochastic Oscillator
  • CTKB 96.77
  • AURA 98.45

About CTKB Cytek Biosciences Inc.

Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Cytek Aurora and Northern Lights systems, are the first full-spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its FSP platform addresses the inherent limitations of other technologies by providing a higher density of information with greater sensitivity, more flexibility, and increased efficiency, all at a lower cost for performance. Geographically, the company generates a majority of its revenue from the United States.

About AURA Aura Biosciences Inc.

Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.

Share on Social Networks: